Mumps Vaccine Market Expected to Reach $3.5 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Mumps Vaccine Market," The mumps vaccine market size valued at $2 billion in 2021, and is estimated to reach $3.5 billion by 2031, growing at a CAGR of 5.8% from 2022 to 2031.

Mumps vaccine is the most efficient way of preventing mumps viral infection in children and elderly population. Mumps vaccine is mainly administered in the form of combination vaccine, which offers resistance against measles, mumps, and rubella virus infections. The vaccine has no side effects; however, some cases may encounter very mild fever or rash. In addition, in some pediatric patients, mumps vaccine is given in the form of MMRV vaccine, which offers resistance against measles, mumps, rubella, and varicella (chickenpox). 

Rise in prevalence of measles, mumps, & rubella; surge in awareness about vaccination among people and increase in R&D activities to develop new vaccine are the major mumps vaccine market trends contributing to the growth of market. Upsurge in incidences of mumps infections in the pediatric population is the major driving factor for the market growth.

For instance, according to the Centers for Disease Control and Prevention (CDC), in U.S., there were 154 cases of mumps infection reported in 2021, and the number raised to 215 cases in 2022 (October). This rise in number of mumps infection cases led to the rise in demand for mumps vaccine for prevention of severe outbreaks in the region. In addition, as the vaccine is administered in the form of combination vaccine, rise in cases of measles and rubella is expected to indirectly lead to rise in sale of mumps vaccines, thus, propelling the growth of the mumps vaccine market.  

Furthermore, the new product launches and product approvals by the public and private players are anticipated to provide a lucrative opportunity for the market. Moreover, vaccine manufacturers are emphasizing on collaboration with organizations including United Nations International Children's Emergency Fund (UNICEF), World Health Organization (WHO), and Global Alliance for Vaccines and Immunization (GAVI) to enhance their vaccination programs in order to reach the maximum population to provide vaccines. This is anticipated to drive the market during the mumps vaccine market forecast period. 

In addition, the government and non-government organizations in the developed as well as developing countries are focusing on creating awareness among the population about vaccination and risk associated with unvaccinated population. Various campaigns and drives are arranged by various organizations that further create awareness among the population about the causes and symptoms about mumps infection. As mumps infection is a contagious infection, hence it is necessary to create awareness among the people about the safety and precautions to be taken to avoid severe outbreaks. In addition, the governments have taken initiatives to spread knowledge and information about the vaccination and immunization, which are expected to help in prevention of infection and avoid any serious conditions associated with it. This further expands the market during mumps vaccine market analysis.  

For instance, according to the article published in March 2022, by Center for Health Protection (Hong Kong), School Immunization Teams (SIT) under the Centre for Health Protection (CHP) is the vaccination scheme set up to provide immunization services to primary one student, primary five female students, and primary six students in Hong Kong under Hong Kong Childhood Immunization Programme (HKCIP). This scheme focuses on providing health knowledge about immunization in students, school staff, parents, and strengthening their awareness about vaccine-preventable diseases. Thus, such initiatives increases the success rate of various vaccination drives in the country, which further rises the demand for vaccines including the mumps vaccine. 

Though presence of several factors drives the growth of mumps vaccine market, few factors also act as a restraint to the market. Factors such as excessive cost and complex procedures associated with the manufacturing and development of vaccines provide a hindrance to the growth of the market. In addition, stringent rules and regulations associated with the development and distribution of mumps vaccines act as a restraint to the market. 

The mumps vaccine market size is segmented on the basis of age group, distribution channel, and region. By age group, the market is bifurcated into pediatric and adult. The pediatric segment was the highest contributor to the market in the year 2021 and is expected to grow at the fastest CAGR of 6.1% during the forecast period. The growth of the segment is attributed to rise in awareness about the mumps vaccination in pediatric population in the developed and developing regions. 

By distribution channel, the market is categorized into hospitals & clinics and vaccination centers. In 2021, the hospitals and clinics segment held the largest mumps vaccine market share of the global mumps vaccine market and is expected to grow at the highest CAGR during the forecast period, which is mainly driven by the considerable number of patient visits to the hospitals for mumps vaccination after the pandemic. 

North America acquires the major mumps vaccine market share in terms of revenue of the mumps vaccine market in 2021, owing to the prevalence of large number of mumps cases in U.S. and other major regions of North America. On the other hand, Asia-Pacific is expected to register fastest growth with the highest CAGR of 8.6% during the forecast period. 

 Key findings of the study 

• By age group, the pediatric segment was the highest contributor to the mumps vaccine industry in 2021. 
• By distribution channel, the hospitals and clinic segment held the highest position in terms of revenue in 2021 and are expected to grow at the highest CAGR during the forecast period. 
• Region wise, North America garnered the largest revenue share in mumps vaccine industry in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.